Kinentia Biosciences was founded in September 2007 to utilize its platform informatics technology called deep data mining (DDM™) to facilitate the development of novel pharmaceutical agents at a fraction of the historic cost. Our DDM™ technique recognizes key risk factors involved in the drug discovery process and has built in process checks to mitigate this risk. Kinentia has two distinct business units Kinentia Services and Kinentia Discovery:

Kinentia Services is a project management and consulting group that is dedicated to helping our clients greatly shorten the timelines of drug discovery and development. By combining our proprietary DDM™ platform technology with our extensive global project management and material procurement capabilities, Kinentia has the ability to reduce both the risk and cost of drug discovery and development. To see how Kinentia’s Services can aid you in your drug discovery and development efforts, please click on the hyperlink above.

Kinentia Discovery is the internal drug discovery arm of Kinentia Biosciences. Using DDM™ Kinentia Discovery has developed several novel agents for the treatment of disease. Kinentia has initiated several programs resulting in the company recognizing several novel agents for the potential treatment of Acute Myeloid Leukemia, Melanoma, Psoriasis and acute pain. For more information on Kinentia Discovery please click on the hyperlink above.

Kinentia’s website is frequently updated so be sure to check back with us soon to find out more information about the company.